Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec 7;8(4):200-9.
doi: 10.1038/nrclinonc.2010.194.

Preclinical development of molecular-targeted agents for cancer

Alberto Ocana  1 , Atanasio Pandiella, Lillian L Siu, Ian F Tannock
Affiliations
Review

Preclinical development of molecular-targeted agents for cancer

Alberto Ocana et al. Nat Rev Clin Oncol. .

Abstract

Molecular-targeted agents are increasingly used for the treatment of cancer. However, the attrition rate for drugs that enter early clinical trials is higher than for other branches of internal medicine, suggesting that preclinical development has not been successful in identifying agents that can modify the outcome of human cancer. New preclinical strategies including genetically engineered mouse models and small-interfering RNAs are being used to evaluate novel agents, and have aided in the development of compounds, such as inhibitors of phosphatidylinositol 3-kinase or poly(ADP-ribose) polymerase. In addition, these techniques have helped in the identification of promising combinations of targeted drugs. In this Review, we describe methods for the preclinical evaluation of novel agents, their limitations, and strategies for improvement.

PubMed Disclaimer

References

    1. Nat Med. 2002 May;8(5):459-65 - PubMed
    1. Cell. 2002 Jan 25;108(2):145-52 - PubMed
    1. Cancer Res. 2004 Jun 1;64(11):3958-65 - PubMed
    1. Cell. 1987 Mar 27;48(6):1023-34 - PubMed
    1. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5 - PubMed

MeSH terms

LinkOut - more resources